RecruitingNot ApplicableNCT06718426

Evaluation of Fertitonex Effects on Semen Parameters in Clinical Varicocele Patient.

Evaluation of Fertitonex Effects on Semen Parameters in Clinical Varicocele Patient, Placebo Controlled Study

Sponsor

Menoufia University

Enrollment

110 participants

Start Date

Dec 1, 2024

Study Type

INTERVENTIONAL

Conditions

Varicocele

Summary

The aim of the study is to evaluate the Fertitonex effects on semen parameters in clinical varicocele patients.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Fertitonex capsule and a drug called Placebo Oral Capsule for people with varicocele. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFertitonex capsule

Fertitonex which contains L- carnitine L-tartarate 300 mg, L-arginine 241mg, vitamin B6 1.1 mg, vitamin B12 1.7 mcg, vitamin D3 2 mcg, vitamin E 6.5 mg, vitamin C 60 mg, selenium 28 mcg, zinc 7.5 mg, folic acid 300 mcg and CoQ 10 enzyme 7.5 mg in each capsule. The dose will be one capsule twice daily for 3 months.

DRUGPlacebo Oral Capsule

placebo oral capsule. the dose is twice daily for 3 months

Locations(1)

Menoufia Faculty of Medicine

Shebin El-Kom, Menoufia, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06718426

Related Trials

Use of the GPX Embolic Device in Patients Requiring Embolization

ACTRN126200011949542 locations